Neuroprotective Effect of Topical Administration of Brimonidine Purite in Rats with Laser-induced Chronic Ocular Hypertension
Banaskiewicz R.1, Vorwerk C. K.1, Ruiz G.2, Wheeler L. A.2, Wolde Mussie E.2
1Department of Ophthalmologie, Otto-von-Guericke-University Magdeburg; 2Department of Biological Sciences, Allergan Inc., Irvine, CA
Purpose: One of the main characteristics in glaucoma is the progressive lost of retinal Ganglion cells (RGC). Therefore is the development of protective drugs for the RGCs an important part in glaucoma research. The aim of this study was to examine the protective effect of topical administration of Brimonidine purite (Alphagan-P) in wistar-rats with laser-induced chronic ocular hypertension.
Method: Intraocular pressure (IOP) was elevated by laser photocoagulation of limbal and episcleral veins. Drug administration was begun on day 10-post laser treatment and continued for 21 days. Drug was applied twice a day in the laser treated eyes only. IOP was monitored weekly before and one hour after drug administration. The RGCs were labelled by retrograde transport with Dextran- Tetra- Methyl- Rhodamine and counted in whole mounted retinas.
Results: Laser treatment caused a two- fold increase in IOP. The treatment with Brimonidine caused a clearly decrease in IOP. The RGC lost 10 days after IOP elevation was 17%. At the end of the experiment in the vehicle treated groups was a 41% decrease in RGCs. In Brimonidin
Zurück | Back